Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. (May 2023)
- Record Type:
- Journal Article
- Title:
- Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. (May 2023)
- Main Title:
- Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
- Authors:
- Fink, Katharina
Gorczyca, Agnes
Alping, Peter
Englund, Simon
Farmand, Susan
Langer-Gould, Annette M
Piehl, Fredrik
McKay, Kyla
Frisell, Thomas
Razaz, Neda - Abstract:
- Background: There is a paucity of information on maternal multiple sclerosis (MS) and risk of adverse pregnancy and perinatal outcomes. Objective: The aim of this study was to determine the association between MS and risks of adverse pregnancy and perinatal outcomes in women with MS. In women with MS, the influence of exposure to disease-modifying therapy (DMT) was also investigated. Methods: Population-based retrospective cohort study on singleton births to mothers with MS and matched MS-free mothers from the general population in Sweden between 2006 and 2020. Women with MS were identified through Swedish health care registries, with MS onset before child's birth. Results: Of 29, 568 births included, 3418 births were to 2310 mothers with MS. Compared with MS-free controls, maternal MS was associated with increased risks of elective caesarean sections, instrumental delivery, maternal infection and antepartum haemorrhage/ placental abruption. Compared with offspring of MS-free women, neonates of mothers with MS were at increased risks of medically indicated preterm birth and being born small for gestational age. DMT exposure was not associated with increased risks of malformations. Conclusions: While maternal MS was associated with a small increased risk of few adverse pregnancy and neonatal outcomes, DMT exposure close to pregnancy was not associated with major adverse outcomes.
- Is Part Of:
- Multiple sclerosis. Volume 29:Number 6(2023)
- Journal:
- Multiple sclerosis
- Issue:
- Volume 29:Number 6(2023)
- Issue Display:
- Volume 29, Issue 6 (2023)
- Year:
- 2023
- Volume:
- 29
- Issue:
- 6
- Issue Sort Value:
- 2023-0029-0006-0000
- Page Start:
- 731
- Page End:
- 740
- Publication Date:
- 2023-05
- Subjects:
- Disease-modifying therapies -- epidemiology -- multiple sclerosis -- pregnancy
Central nervous system -- Diseases -- Periodicals
Myelin sheath -- Diseases -- Periodicals
Inflammation -- Periodicals
Multiple sclerosis -- Periodicals
Central Nervous System Diseases -- Periodicals
Demyelinating Diseases -- Periodicals
Inflammation -- Periodicals
Multiple Sclerosis -- Periodicals
Système nerveux central -- Maladies -- Périodiques
Gaine de myéline -- Maladies -- Périodiques
Inflammation (Pathologie) -- Périodiques
Sclérose en plaques -- Périodiques
Electronic journals
616.834005 - Journal URLs:
- http://msj.sagepub.com/ ↗
http://search.ebscohost.com/login.aspx?direct=true&db=a2h&jid=DZL&site=ehost-live ↗
http://www.uk.sagepub.com/home.nav ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1352-4585;screen=info;ECOIP ↗
http://www.arnoldpublishers.com/journals/pages/mul_scl/13524585.htm ↗ - DOI:
- 10.1177/13524585231161492 ↗
- Languages:
- English
- ISSNs:
- 1352-4585
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26441.xml